A role of targeted therapies combined with chemotherapy in the outcome of metastatic colorectal cancer in the clinical pratice
Keywords:
Metastatic colo-rectal cancer, targeted therapies, outcome studiesAbstract
Aims. To evaluate in the clinical practice the impact on relative survival of patients with metastatic colo-rectal carcinoma of the addiction of “targeted therapies”, combined with chemoterapy. Matherials and methods. A descriptive and retrospective study on 457 consecutive patients with metastatic colo-rectal carcinoma and accepted between Jan. 1st, 1994 and Mar. 31th, 2009 at the Clinical Oncology Unit of Azienda Ospedaliero – Universitaria of Ferrara. Results. 223 out of 457 enrolled patients (48.8%) received during the disease a fluoro-folate containig therapy, 172 (37.6%) also oxaliplatin and/or irinotecan, and 62 (13.6%) also “targeted therapies” (bevacizumab and/or cetuximab). Overall median survival was 8 months (C.I. 95%: 5-11 months). The comparison between patients having been submitted to “targeted therapies” or not showed a statistically significant difference (62.67 vs. 67.18 months; p<0.0001). In the subgroup of patients with age ≤ 70 years a statistically significative correlation has been shown as for number of chemotherapy lines (p<0.0001); kind of chemotherapy (p<0.0001), serum levels of CEA (p=0.006), CA19.9 (p=0.01), alkaline phosphatase (p=0.003), metastatic site (liver p=0.01, peritoneal p=0.05), performance status (p<0.001), presence of weigth loss (p=0.03) Conclusions. The above results confirm the literature data on the efficacy of the addiction of “targeted therapies” (bevacizumab and/or cetuximab) to the treatment scheme of advanced colo-rectal cancer, and the opportunity to employ in the sub-sequent lines all the active drugs (chemotherapy and monoclonal antibodies).Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.